| Diseases |
miRNAs |
Pathogenic contribution |
Cells |
|
Systemic lupus erythematosus [24,25,129] |
miR-146a |
Targets STAT-1 and IRF-5, negative regulator of Type I IFN pathway |
PBMCs |
| miR-148a |
Target DNMT1 directly and indirectly, induces DNA hypomethylation and the expression autoimmune-associated genes |
CD4+ T cells |
| miR-125a |
Targets KLF13, Negative regulator of inflammatory
chemokine RANTES |
PBMCs |
| miR-21 |
Target RAS, induces DNA hypomethylation |
CD4+ T cells |
|
Rheumatoid Arthritis [130-134] |
miR-146a |
Targets FAF1, negative regulator of T cell apoptosis |
PBMC, CD4+ T cells, Th-17 cells, synovial fibroblasts |
| miR-155 |
Targets Matrix metalloproteinase
(MMP)-3/1 in RASFs, Regulation of
inflammation and potentially involved in RASFs mediated tissue damages |
PBMC, Th-17 cell, synovial fibroblasts |
| miR-124a |
Targets cyclin-dependent kinase 2 (CDK-2) and chemokine MCP-1, negative regulator of cell proliferation and MCP-1 secretion |
synoviocytes |
|
Multiple sclerosis [135-138] |
miR-326 |
Targets Ets-1, Promotes Th-17 cell
differentiation |
CD4+ T cells |
| miR-17-5P, miR-20a |
Potentially involved in the regulation of T cell activation |
CD4+ T cells |
| miR-34a, miR-155 and miR-326 |
Targets CD47, promotes phagocytosis of myelin by releasing macrophage from inhibitory signaling |
MS lesion |
